Wales' HPV vacc catch up campaign accelerated
The government of Wales has decided to accelerate a catch-up campaign for the UK-based drug major GlaxoSmithKline's Cervarix (human papillomavirus vaccine). The routine immunization program was launched in the fall of 2008, with close to 90% of girls aged 12-13 years already receiving their first dose and about three quarters their second.
Sara Woolnough, Cancer Research UK's head of policy, said: "this plan to accelerate the vaccination of girls and young women against cervical cancer in Wales is welcome news indeed."
Previously, the Welsh Assembly had decided on a two-year campaign, though this has now been expanded so that all females born between September 1991 and August 1995, will be offered Cervarix ahead of schedule. The agent provides protection against the HPV strains responsible for 70% of cervical cancer cases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze